Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trialDiwakar Davar, Janis M. Taube, Robert M. Morrison et al.|Cancer Cell|2024Cited by 60
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Clinical Cancer Research|2021Cited by 26
Detection of Alternative Lengthening of Telomeres via Chromogenic In Situ Hybridization for the Prognostication of PanNETs and Other NeoplasmsChristopher M. Heaphy, Dennis Hsu, Janie Y. Zhang et al.|Modern Pathology|2024Cited by 6
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G. Najjar, Ahmad A. Tarhini, Dustin McCurry et al.|Unknown|2023Cited by 0